Skip to main content

Table 1 Raw values used for analyses

From: A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

   Incidence Mort. US Gov't
YLL (thousands)
WHO
DALY (thousands)
Medicare Spend$ (millions) National spend $ (billions) Lost
prod. (billions)
NCI Funding (millions) AYLL YLLPI
Bladder Blad 70530 14680 154.4 128.7 1023 3.466 1.977 22.6 10.52 2.19
Brain, ONS Br/cns 22020 13140 290.8   293 3.715 5.851 193.1 22.13 13.21
Breast Breast 209060 40230 761.3 612.5 1375 13.886 10.879 631.2 18.92 3.64
Cervix Cerv 12200 4210 104.7 114.1 73 1.425 1.808 76.5 24.87 8.58
Colon/rectum Co/rec 142570 51370 764.6 542.1 3101 12.155 12.802 270.4 14.88 5.36
Esophogus Esoph 16640 14500 214.2 122 386 1.071 --- 30.5 14.77 12.87
Hogkin lymph. H lym 8490 1320 29.8 288.7** 1350* 10.168* 0.829 14.6 22.58 3.51
Kidney Kidney 58240 13040 195.7 --- 685 3.058 3.633 90.0 15.01 3.36
Leukemia leuk 43050 21840 355.2 210.5 695 4.507 5.880 295.8 16.26 8.25
Liver Liver 24120 18910 292.2 137.8 278 --- 4.638 72.6 15.45 12.11
Lung Lung 222520 157300 2369 1247.6 4238 10.315 38.953 281.9 15.06 10.65
Myeloma Myel 20180 10650 148.1 ** --- --- --- 48.5 13.91 7.34
NH Lymphoma NHL 65540 20210 292.4 ** * * 5.755 122.4 14.47 4.46
Oral,pharnyx Oral 36540 7880 138 85.4 --- --- --- 13.9 17.51 3.78
Ovary Ovary 21880 13850 248.8 145 507 4.379 2.945 112.3 17.96 11.37
Pancreas Panc 43140 36800 498.4 237.7 771 1.884 7.058 97.1 13.54 11.55
Prostate Pros 217730 32050 267.4 225 2294 9.862 3.538 300.5 8.34 1.23
Melanoma (skin) Melo 68130 8700 150.7 120.6 181 1.906 3.298 102.3 17.32 2.21
Stomach Stom 21000 10570 176 106.9 624 1.550 3.454 14.5 16.65 8.38
Testes Test 8480 350 11.8 --- --- --- 0.472 6.3 33.71 1.39
Uterus Uter 43470 7950 122.8 75.5 340 2.330 1.101 14.2 15.45 2.82
  1. Incidence, mortality, YLL, three measures of economic cost (Medicare payments, overall medical spending, and lost productivity), research funding by the NCI and calculated values for AYLL and YLLPI using data from the table for the 21 cancers for which we had sufficient data. The symbol --- indicates that data for those values were not available, * indicates that for Medicare and National expenditure cost estimations the categories "Hodgkin's lymphoma" and "non-Hodgkin's lymphoma" were combined in those reports, ** indicates that for for World Health Organization (WHO) DALY estimates the categories "Hodgkin's lymphoma", "non-Hodgkin's lymphoma" and "myeloma" were combined in those reports.